MCID: PPL018
MIFTS: 47

Papillary Adenocarcinoma

Categories: Cancer diseases

Aliases & Classifications for Papillary Adenocarcinoma

MalaCards integrated aliases for Papillary Adenocarcinoma:

Name: Papillary Adenocarcinoma 12 14 69
Infiltrating and Papillary Adenocarcinoma 12
Infiltrating Papillary Adenocarcinoma 12
Papillary Adenocarcinoma Nos 12
Adenocarcinoma, Papillary 41
Adenocarcinoma Papillary 51

Classifications:



External Ids:

Disease Ontology 12 DOID:3112
MeSH 41 D000231
NCIt 46 C2853 C7438

Summaries for Papillary Adenocarcinoma

Disease Ontology : 12 An adenocarcinoma that derives from epithelial cells originating in glandular tissue, which form complex papillary structures and exhibit compressive, destructive growth that replaces the normal tissue.

MalaCards based summary : Papillary Adenocarcinoma, also known as infiltrating and papillary adenocarcinoma, is related to eccrine papillary adenocarcinoma and aggressive digital papillary adenocarcinoma. An important gene associated with Papillary Adenocarcinoma is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are Gastric cancer and Cytoskeletal Signaling. The drugs Bevacizumab and Everolimus have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lung and cervix, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 72 Papillary adenocarcinoma is a histological form of lung cancer that is diagnosed when the malignant... more...

Related Diseases for Papillary Adenocarcinoma

Diseases related to Papillary Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 331)
# Related Disease Score Top Affiliating Genes
1 eccrine papillary adenocarcinoma 34.0 KRT7 PGR
2 aggressive digital papillary adenocarcinoma 33.6 CEACAM5 MUC1 S100B
3 papillary serous adenocarcinoma 31.9 KRT7 NKX2-1 PGR
4 adenocarcinoma 31.2 CDH1 ERBB2 MST1R MUC1
5 papillary adenoma 30.1 KRT7 NKX2-1 VIM
6 pulmonary sclerosing hemangioma 30.0 KRT7 NKX2-1
7 thymus adenocarcinoma 30.0 CEACAM5 KRT7
8 sclerosing hemangioma 29.9 KRT7 MUC1 NKX2-1
9 endometrial adenocarcinoma 29.7 ERBB2 KRT7 PGR
10 polymorphous low-grade adenocarcinoma 29.6 MUC1 S100B VIM
11 transitional cell carcinoma 29.5 CDH1 ERBB2 KRT7
12 cholecystitis 29.1 CDH1 MUC1 MUC2
13 microinvasive gastric cancer 28.9 CDH1 CEACAM5 MUC2
14 squamous cell carcinoma 28.7 CDH1 CEACAM5 ERBB2 KRT7 MUC1 NME1
15 lung cancer susceptibility 3 28.4 CDH1 CEACAM5 ERBB2 KRT7 MUC1 NKX2-1
16 cystadenocarcinoma 28.3 CEACAM5 KRT7 MUC1 MUC2 PGR VIM
17 ovarian cancer 1 27.8 CDH1 CEACAM5 ERBB2 KRT7 MUC1 NME1
18 gastric cancer 27.6 CDH1 CEACAM5 ERBB2 MUC1 MUC2 NME1
19 ovarian cancer 27.3 CDH1 ERBB2 KRT7 MUC1 MUC2 NME1
20 gastric papillary adenocarcinoma 12.2
21 fallopian tube papillary adenocarcinoma 12.1
22 lung papillary adenocarcinoma 12.1
23 peritoneal serous papillary adenocarcinoma 12.1
24 nasopharyngeal carcinoma 3 11.1
25 malignant peritoneal mesothelioma 10.5 MUC1 VIM
26 papillary tumor of the pineal region 10.5 MUC1 VIM
27 middle ear adenoma 10.5 KRT7 MUC1
28 glandular cystitis 10.5 KRT7 MUC1
29 adenofibroma 10.5 MUC1 VIM
30 thyroiditis 10.5
31 lung acinar adenocarcinoma 10.5 KRT7 NKX2-1
32 lymphangiomatosis 10.5 PGR VIM
33 nephrogenic adenoma 10.5 KRT7 MUC1
34 adenomyoma 10.5 KRT7 MUC1
35 ovarian germ cell teratoma 10.5 KRT7 NKX2-1
36 small cell carcinoma of the bladder 10.5 KRT7 NKX2-1
37 ovarian germ cell cancer 10.5 KRT7 NKX2-1
38 epulis 10.4 PGR VIM
39 reticulum cell sarcoma 10.4 MUC1 VIM
40 medulloepithelioma 10.4 KRT7 VIM
41 benign breast phyllodes tumor 10.4 PGR VIM
42 female reproductive endometrioid cancer 10.4 KRT7 PGR
43 bronchiolo-alveolar adenocarcinoma 10.4 KRT7 NKX2-1
44 well-differentiated liposarcoma 10.4 KRT7 MUC1
45 metanephric adenoma 10.4 KRT7 VIM
46 adenomatoid tumor 10.4 KRT7 VIM
47 cribriform carcinoma 10.4 KRT7 PGR
48 apocrine adenoma 10.4 CEACAM5 MUC1
49 intestinal perforation 10.4 KRT7 NKX2-1
50 sertoli cell tumor 10.4 MUC1 VIM

Graphical network of the top 20 diseases related to Papillary Adenocarcinoma:



Diseases related to Papillary Adenocarcinoma

Symptoms & Phenotypes for Papillary Adenocarcinoma

GenomeRNAi Phenotypes related to Papillary Adenocarcinoma according to GeneCards Suite gene sharing:

25 (show all 31)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.91 S100B
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.91 VIM MST1R
3 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.91 MST1R
4 Increased shRNA abundance (Z-score > 2) GR00366-A-12 9.91 NME1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-13 9.91 NME1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.91 MST1R
7 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.91 MST1R
8 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.91 VIM
9 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.91 MST1R
10 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.91 MST1R
11 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.91 ERBB2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.91 ERBB2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.91 ERBB2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.91 MST1R
15 Increased shRNA abundance (Z-score > 2) GR00366-A-172 9.91 NME1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.91 VIM
17 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.91 VIM MST1R
18 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.91 VIM
19 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.91 VIM
20 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.91 ERBB2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.91 VIM
22 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.91 VIM
23 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.91 ERBB2 MST1R
24 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.91 MST1R
25 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.91 MST1R
26 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.91 NME1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.91 ERBB2 S100B VIM
28 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.91 MST1R
29 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.91 S100B ERBB2 VIM MST1R NME1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-97 9.91 NME1
31 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.26 ERBB2 VIM MST1R MUC1

MGI Mouse Phenotypes related to Papillary Adenocarcinoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.7 CDH1 ERBB2 MST1R MUC2 NKX2-1 NME1
2 homeostasis/metabolism MP:0005376 9.61 CDH1 ERBB2 KRT7 MST1R MUC2 NKX2-1
3 neoplasm MP:0002006 9.1 CDH1 ERBB2 MUC2 NKX2-1 NME1 PGR

Drugs & Therapeutics for Papillary Adenocarcinoma

Drugs for Papillary Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 41)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 2 216974-75-3
2
Everolimus Approved Phase 2 159351-69-6 6442177
3
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
4
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
5
nivolumab Approved Phase 2 946414-94-4
6
Gemcitabine Approved Phase 2 95058-81-4 60750
7
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
8
Olaparib Approved Phase 1, Phase 2 763113-22-0 23725625
9
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
10
Cediranib Investigational Phase 1, Phase 2 288383-20-0 9933475
11
Maleic acid Experimental Phase 1, Phase 2 110-16-7 444266
12
Doxil Approved June 1999 Phase 2 31703
13 Angiogenesis Inhibitors Phase 2
14 Angiogenesis Modulating Agents Phase 2
15 Anti-Bacterial Agents Phase 2
16 Antibiotics, Antitubercular Phase 2
17 Antibodies Phase 2
18 Antibodies, Monoclonal Phase 2
19 Antifungal Agents Phase 2
20 Anti-Infective Agents Phase 2
21 Endothelial Growth Factors Phase 2
22 Immunoglobulins Phase 2
23 Immunosuppressive Agents Phase 2
24 Liver Extracts Phase 2
25 Mitogens Phase 2
26 Antimetabolites Phase 2
27 Antimetabolites, Antineoplastic Phase 2
28 Antiviral Agents Phase 2
29 Aromatase Inhibitors Phase 2
30 Estrogen Antagonists Phase 2
31 Estrogens Phase 2
32 Hormone Antagonists Phase 2
33 Hormones Phase 2
34 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
35 Steroid Synthesis Inhibitors Phase 2
36 Poly(ADP-ribose) Polymerase Inhibitors Phase 1, Phase 2
37 Protein Kinase Inhibitors Phase 1, Phase 2
38
Atrasentan Phase 2 173937-91-2, 195733-43-8 159594
39 Endothelin Receptor Antagonists Phase 2
40 taxane Phase 2
41 Topoisomerase Inhibitors Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
2 Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Recruiting NCT02978625 Phase 2
3 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
4 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT02101775 Phase 2 Gemcitabine Hydrochloride;WEE1 Inhibitor AZD1775
5 Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Active, not recruiting NCT02283658 Phase 2 Everolimus;Letrozole
6 Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Active, not recruiting NCT01116648 Phase 1, Phase 2 Cediranib Maleate;Olaparib
7 Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma Terminated NCT00653328 Phase 2 atrasentan hydrochloride;doxil
8 Research Study in Patients With Advanced Ovarian Epithelial Cancer Withdrawn NCT00053235

Search NIH Clinical Center for Papillary Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma, papillary

Genetic Tests for Papillary Adenocarcinoma

Anatomical Context for Papillary Adenocarcinoma

MalaCards organs/tissues related to Papillary Adenocarcinoma:

38
Thyroid, Lung, Cervix, Ovary, Liver, Lymph Node, Salivary Gland

Publications for Papillary Adenocarcinoma

Articles related to Papillary Adenocarcinoma:

(show top 50) (show all 362)
# Title Authors Year
1
Endonasal endoscopic nasopharyngectomy for the treatment of nasopharyngeal papillary adenocarcinoma: Report of a rare case. ( 29287881 )
2018
2
Pulmonary papillary adenocarcinoma with<i>Aspergillus versicolor</i>infection in a dog. ( 29234587 )
2018
3
The So-Called Aggressive Digital Papillary Adenocarcinoma Is Epithelial-Myoepithelial Carcinoma. ( 29384814 )
2018
4
Aggressive digital papillary adenocarcinoma: A clinicopathological study of 19 cases. ( 28495496 )
2017
5
Primary papillary adenocarcinoma of the lung: Report of two cases. ( 28474664 )
2017
6
Response to: Cutaneous papillary adenocarcinoma in situ. ( 28299799 )
2017
7
An Alpha Fetoprotein Producing Gastric Tumor with Yolk Sac, Hepatoid and Papillary Adenocarcinoma Components. ( 29207718 )
2017
8
Masson's Tumor Masquerading as a Papillary Adenocarcinoma on Fine Needle Aspiration Cytology: A Case Report. ( 28272657 )
2017
9
Primary thyroid-like low-grade nasopharyngeal papillary adenocarcinoma: A case report and literature review. ( 29381996 )
2017
10
Clinicopathological and molecular stability and methylation analyses of gastric papillary adenocarcinoma. ( 28830689 )
2017
11
Highly variable clinical feature and course of aggressive digital papillary adenocarcinoma. ( 29194742 )
2017
12
Nasopharyngeal papillary adenocarcinoma. ( 29236265 )
2017
13
Thyroid-like low-grade nasopharyngeal papillary adenocarcinoma with squamous differentiation: A novel histological finding. ( 28601658 )
2017
14
Aggressive digital papillary adenocarcinoma: treatment with Mohs micrographic surgery and an update of the literature. ( 28832985 )
2017
15
Lymphovascular invasion and lymph node metastasis rates in papillary adenocarcinoma of the stomach: implications for endoscopic resection. ( 29280035 )
2017
16
Endoscopic submucosal dissection for papillary adenocarcinoma of the stomach: is it really safe? ( 28271420 )
2017
17
Cronkhite-Canada Syndrome with a Major Duodenal Papillary Adenocarcinoma. ( 28924129 )
2017
18
Aggressive Digital Papillary Adenocarcinoma of the Hand Presenting as a Felon. ( 28421154 )
2017
19
Cutaneous papillary adenocarcinoma in situ. ( 28164358 )
2017
20
Mohs Micrographic Surgery as a Digit-Sparing Treatment for Aggressive Digital Papillary Adenocarcinoma. ( 28291063 )
2017
21
Treatment of endolymphatic sac tumour (Papillary adenocarcinoma) of the temporal bone. ( 27330425 )
2016
22
Malignant transformation of alveolar adenoma to papillary adenocarcinoma: a case report. ( 27162700 )
2016
23
Papillary adenocarcinoma of the renal pelvis with renal calculus: A rare case report. ( 27123287 )
2016
24
Papillary adnexal neoplasm (Aggressive digital papillary adenocarcinoma) on the ankle of a 15 year old girl: case report and review of literature from a pediatric perspective. ( 27535353 )
2016
25
Villoglandular papillary adenocarcinoma: case report. ( 28293348 )
2016
26
Low-grade nasopharyngeal papillary adenocarcinoma: a case report and review of the literature. ( 27274289 )
2016
27
Low-grade papillary adenocarcinoma of nasopharynx with expression of thyroid transcription factor-1: Case report and review of literature. ( 27721286 )
2016
28
Villoglandular papillary adenocarcinoma of the uterine cervix: A report of 4 cases and a review of the literature. ( 26870293 )
2016
29
A retrospective review of 11 cases of villoglandular papillary adenocarcinoma of the uterine cervix and a review of the literature. ( 26998142 )
2016
30
Aggressive papillary adenocarcinoma on atypical localization: A unique case report. ( 27428196 )
2016
31
Papillary adenocarcinoma with tentacular processes (with video). ( 27302875 )
2016
32
Thyroid-like low-grade nasopharyngeal papillary adenocarcinoma: A case report. ( 28105348 )
2016
33
An unexpected digital papillary adenocarcinoma of the thumb. ( 27990456 )
2016
34
Aggressive Digital Papillary Adenocarcinoma With Multiple Organ Metastases: A Case Report and Review of the Literature. ( 27870729 )
2016
35
Role of Radiotherapy in Aggressive Digital Papillary Adenocarcinoma. ( 27098633 )
2016
36
Metastatic Papillary Adenocarcinoma in a 22-Year-Old: Is Her History of Mayer-Rokitansky-KA1ster-Hauser Syndrome Causative or Incidental? ( 27987200 )
2016
37
Clinicopathological Features of Low-Grade Thyroid-Like Nasopharyngeal Papillary Adenocarcinoma. ( 27384157 )
2016
38
Spreading Patterns, Prognostic factors and Treatment Outcomes of Nasopharyngeal Papillary Adenocarcinoma and Salivary Gland-type Carcinomas. ( 26118586 )
2015
39
"Apocrine Hidrocystoma and Cystadenoma"-like Tumor of the Digits or Toes: A Potential Diagnostic Pitfall of Digital Papillary Adenocarcinoma. ( 26523544 )
2015
40
Next-generation sequencing reveals rare genomic alterations in aggressive digital papillary adenocarcinoma. ( 26386519 )
2015
41
Primary thyroid-like papillary adenocarcinoma of the nasal septum: a case report. ( 25651353 )
2015
42
Aggressive digital papillary adenocarcinoma - a rare malignant tumor of the sweat glands: two case reports and a review of the literature. ( 25848311 )
2015
43
Is endoscopic submucosal dissection safe for papillary adenocarcinoma of the stomach? ( 25852280 )
2015
44
Aggressive Digital Papillary Adenocarcinoma: Case Report of a Positive Sentinel Lymph Node and Discussion of Utility of Sentinel Lymph Node Biopsy. ( 25954845 )
2015
45
Endoscopic ultrasonography-guided drainage of infected intracystic papillary adenocarcinoma of the liver. ( 26412329 )
2015
46
Digital Papillary Adenocarcinoma: Presentation, Natural History and Management. ( 26266016 )
2015
47
Low-grade papillary adenocarcinoma of minor salivary glands in pregnancy. ( 26960505 )
2015
48
Right visual loss due to choroidal metastasis of a papillary adenocarcinoma of the lung: a case report. ( 26662155 )
2015
49
Aggressive Digital Papillary Adenocarcinoma. ( 26576210 )
2015
50
Primary serous papillary adenocarcinoma of the fallopian tube. ( 25163242 )
2014

Variations for Papillary Adenocarcinoma

Expression for Papillary Adenocarcinoma

Search GEO for disease gene expression data for Papillary Adenocarcinoma.

Pathways for Papillary Adenocarcinoma

Pathways related to Papillary Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.34 CDH1 ERBB2 MUC2 PGR
2 11.75 CDH1 KRT7 MUC1 VIM
3 11.52 CDH1 CEACAM5 MUC1
4
Show member pathways
11.37 ERBB2 PGR S100B
5 10.58 CDH1 VIM
6 10.29 CDH1 ERBB2 MST1R

GO Terms for Papillary Adenocarcinoma

Molecular functions related to Papillary Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.26 MST1R NKX2-1 NME1 PGR
2 identical protein binding GO:0042802 9.17 CDH1 CEACAM5 ERBB2 NME1 PGR S100B

Sources for Papillary Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....